<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-13T11:53:36Z</responseDate>
  <request identifier="oai:figshare.com:article/33518235" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33518235</identifier>
        <datestamp>2026-09-22T15:38:59Z</datestamp>
        <setSpec>category_4</setSpec>
        <setSpec>category_7</setSpec>
        <setSpec>category_15</setSpec>
        <setSpec>category_19</setSpec>
        <setSpec>category_873</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>portal_63</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Design and Evaluation of Selective Positive Allosteric
Modulators Targeting Kainate Receptors</dc:title>
          <dc:creator>Thomas Colson (11105053)</dc:creator>
          <dc:creator>Yasmin Bay (24757197)</dc:creator>
          <dc:creator>Alexandra Manos-Turvey (2072650)</dc:creator>
          <dc:creator>Giacomo Baudino (24757200)</dc:creator>
          <dc:creator>Bastiaan Poldermans (24757203)</dc:creator>
          <dc:creator>Eric Goffin (827887)</dc:creator>
          <dc:creator>Marine Piette (25090786)</dc:creator>
          <dc:creator>Cindy Lesenfants (22168280)</dc:creator>
          <dc:creator>Marie Leclercq (24757206)</dc:creator>
          <dc:creator>Jette S. Kastrup (141346)</dc:creator>
          <dc:creator>Bernard Pirotte (1684396)</dc:creator>
          <dc:creator>Anders S. Kristensen (689761)</dc:creator>
          <dc:creator>Pierre Francotte (1701325)</dc:creator>
          <dc:subject>Biochemistry</dc:subject>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Neuroscience</dc:subject>
          <dc:subject>Pharmacology</dc:subject>
          <dc:subject>Chemical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>terminated ), trifluorinated</dc:subject>
          <dc:subject>surrounding hydrophobic pocket</dc:subject>
          <dc:subject>showed preferential potentiation</dc:subject>
          <dc:subject>receptor subtypes tested</dc:subject>
          <dc:subject>predicted poses rather</dc:subject>
          <dc:subject>medicinal chemistry framework</dc:subject>
          <dc:subject>experimentally confirmed interactions</dc:subject>
          <dc:subject>emerging therapeutic targets</dc:subject>
          <dc:subject>nitro benzyl analogue</dc:subject>
          <dc:subject>benzyl series revealed</dc:subject>
          <dc:subject>benzothiadiazine ampa receptor</dc:subject>
          <dc:subject>lacked kar activity</dc:subject>
          <dc:subject>detectable activity across</dc:subject>
          <dc:subject>acidic substituents may</dc:subject>
          <dc:subject>7y &lt;/ b</dc:subject>
          <dc:subject>7u &lt;/ b</dc:subject>
          <dc:subject>7q &lt;/ b</dc:subject>
          <dc:subject>fluorinated benzyl analogue</dc:subject>
          <dc:subject>promising starting point</dc:subject>
          <dc:subject>preferentially potentiated gluk3</dc:subject>
          <dc:subject>3 allosteric sites</dc:subject>
          <dc:subject>results establish 1</dc:subject>
          <dc:subject>polar benzyl substituents</dc:subject>
          <dc:subject>selective kar pams</dc:subject>
          <dc:subject>dioxides (&lt; b</dc:subject>
          <dc:subject>2 +&lt;/ sup</dc:subject>
          <dc:subject>minimal glua2 modulation</dc:subject>
          <dc:subject>phenethyl substituents</dc:subject>
          <dc:subject>modulatory activity</dc:subject>
          <dc:subject>identify kar</dc:subject>
          <dc:subject>polar region</dc:subject>
          <dc:subject>may represent</dc:subject>
          <dc:subject>inactive across</dc:subject>
          <dc:subject>fluorinated derivatives</dc:subject>
          <dc:subject>benzothiadiazine 1</dc:subject>
          <dc:subject>tractable chemotype</dc:subject>
          <dc:subject>systematic diversification</dc:subject>
          <dc:subject>synthesized via</dc:subject>
          <dc:subject>short nitrile</dc:subject>
          <dc:subject>remaining inactive</dc:subject>
          <dc:subject>remain scarce</dc:subject>
          <dc:subject>psychiatric disorders</dc:subject>
          <dc:subject>pharmacological testing</dc:subject>
          <dc:subject>optimally engaged</dc:subject>
          <dc:subject>nitrobenzyl derivative</dc:subject>
          <dc:subject>neurodegenerative diseases</dc:subject>
          <dc:subject>including nitrile</dc:subject>
          <dc:subject>hek cells</dc:subject>
          <dc:description>Kainate-type ionotropic glutamate receptors (KARs) are emerging
therapeutic targets for the modulation of excitatory neurotransmission
in epilepsy, psychiatric disorders, and neurodegenerative diseases,
yet selective positive allosteric modulators (PAMs) remain scarce.
Starting from the benzothiadiazine AMPA receptor (AMPAR) PAM BPAM344
(&lt;b&gt;1&lt;/b&gt;), we pursued a structure-based scaffold repurposing
strategy to identify KAR-directed analogues. A focused library of
benzothiadiazine 1,1-dioxides (&lt;b&gt;7a&lt;/b&gt;–&lt;b&gt;7z&lt;/b&gt;) was designed through systematic diversification at the N4 position
and modulation of the C7 substituent (H, F, and Cl). Compounds were
synthesized via a convergent route involving benzothiadiazine core
assembly, N4 alkylation with aliphatic (including nitrile-terminated),
trifluorinated, benzyl, or phenethyl substituents, followed by reduction
to the corresponding 3,4-dihydro derivatives. All compounds were fully
characterized and evaluated for modulatory activity at GluA2 and GluK1–3
receptors using Ca&lt;sup&gt;2+&lt;/sup&gt; fluorescence assays in HEK cells.
Clear structure–activity relationships (SAR) were established.
Short nitrile-terminated aliphatic substituents (&lt;b&gt;7a&lt;/b&gt;–&lt;b&gt;7g&lt;/b&gt;) retained GluA2 potentiation but lacked KAR activity, indicating
that flexible polar chains favor AMPAR selectivity. In contrast, the
N4-benzyl series revealed a more complex structure–activity
relationship. The para-nitro benzyl analogue &lt;b&gt;7y&lt;/b&gt; was inactive
across the receptor subtypes tested, whereas the 3-fluoro-4-nitrobenzyl
derivative &lt;b&gt;7q&lt;/b&gt; showed preferential potentiation of GluK1
and GluK3, with minimal GluA2 modulation. Notably, the meta-fluorinated
benzyl analogue &lt;b&gt;7u&lt;/b&gt; preferentially potentiated GluK3 while
remaining inactive at GluK1, GluK2, and GluA2, whereas the other fluorinated
derivatives were devoid of detectable activity across the receptor
subtypes tested. These findings reveal a distinct subtype-dependent
SAR and support the existence of a spatially constrained polar microenvironment
within the GluK1/3 allosteric sites, which appears to be optimally
engaged by rigid para-polar benzyl substituents. In line with our
docking observations, acidic substituents may further exploit this
polar region while the core scaffold remains favorably accommodated
in the surrounding hydrophobic pocket. On the basis of the pharmacological
testing, meta-fluorination appears to further refine subtype selectivity
toward GluK3 and may represent a promising starting point for further
exploratory work. Collectively, these results establish 1,2,4-benzothiadiazine
1,1-dioxides as a tractable chemotype for the development of subtype-selective
KAR PAMs and provide a medicinal chemistry framework for second-generation
optimization, while the docking-derived contacts should be regarded
as plausible structural hypotheses rather than experimentally confirmed
interactions, given that they are based on SwissDock-predicted poses
rather than a crystallographic ligand–receptor complex.</dc:description>
          <dc:date>2026-09-22T00:00:00Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1021/acsomega.6c03618.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Design_and_Evaluation_of_Selective_Positive_Allosteric_Modulators_Targeting_Kainate_Receptors/33518235</dc:relation>
          <dc:rights>CC BY-NC 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
